CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
非霍奇金淋巴瘤与多发性骨髓瘤患者 CAR-T 治疗后对 COVID-19 疫苗接种的反应
英文原题：Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
查看英文原题
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
COVID-19会对癌症患者造成不利影响。多项研究发现，血液系统恶性肿瘤患者血清转换率低于无癌症者。非霍奇金淋巴瘤（NHL）和多发性骨髓瘤（MM）患者因体液和细胞免疫受损及免疫抑制治疗而处于免疫低下状态。CAR-T 已广泛用于NHL和MM，但这些患者接种COVID-19疫苗后的血清转换情况所知有限。本研究评估CAR-T 受者接种疫苗后的SARS-CoV-2刺突蛋白结合IgG抗体水平。104次CAR-T 输注中，19名患者治疗后发生已知COVID-19感染；研究检测其中17名患者疫苗接种后的抗体滴度，仅5人（29%）产生临床相关水平的抗体反应（>250 IU/mL）。
展开英文摘要原文
COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer.
Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about seroconversion rates after COVID-19 vaccination among these populations.
We evaluated SARS-CoV-2 spike-binding IgG antibody levels following COVID-19 vaccination among NHL and MM CAR T therapy recipients. Out of 104 CAR T infusions, 19 patients developed known COVID-19 infection post-CAR T.
We tested 17 patients that received CAR T for antibody spike titers post COVID-19 vaccination, only 29 % (n = 5) were able to mount a clinically relevant antibody response (>250 IU/mL).
论文信息
- 作者
- Wiedmeier-Nutor JE、Iqbal M、Rosenthal AC、Bezerra ED、Garcia-Robledo JE、Bansal R、Johnston PB、Hathcock M
- 单位
- Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ. Electronic address: Wiedmeier.Julia@mayo.edu.
- 期刊
- Clinical lymphoma, myeloma & leukemia2023 Jun
- 原文标识
- PubMed 37003846 · DOI 10.1016/j.clml.2023.03.002
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →